Cargando…
Treatment of relapsed acute leukemia by Ara C plus donor lymphocyte infusion using CD34+ cells reserved at the time of allogeneic transplantation
Currently, there is no standard therapy available for relapsed acute leukemia after allogeneic hematopoietic cell transplantation (allo-HCT). In this study, we evaluated the efficacy of cytoreduction with cytarabine followed by granulocyte colony-stimulating factor (G-CSF)-primed donor lymphocyte in...
Autores principales: | YJ, Lee, DW, Back, HC, Cho, JH, Moon, SK, Sohn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asia-Pacific Blood and Marrow Transplantation Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261720/ https://www.ncbi.nlm.nih.gov/pubmed/37325245 http://dx.doi.org/10.31547/bct-2019-015 |
Ejemplares similares
-
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation
por: Zhao, Peng, et al.
Publicado: (2021) -
Combination of Donor Lymphocyte Infusion and Blinatumomab for B-Cell Lymphoblastic Lymphoma Relapse after Allogeneic Stem-Cell Transplantation
por: Mori, Jinichi, et al.
Publicado: (2023) -
Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells
por: Kwon, Yong-Rim, et al.
Publicado: (2020) -
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
por: Liberatore, Carmine, et al.
Publicado: (2022) -
Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion
por: McCurdy, Shannon R.
Publicado: (2022)